Docetaxel (Doc) Versus New Androgen Receptor-Targeted Agent (Art) In Metastatic Castrate-Resistant Prostate Cancer (Mcrpc) Patients (Pts) Having Received Abiraterone (Abi) Or Enzalutamide (Enza) As First-Line (L1)
JOURNAL OF CLINICAL ONCOLOGY（2020）
摘要
109Background: The main treatments for mCRPC are 2 new ART (ABI, ENZA) and 2 taxanes [doctaxel (DOC) and Cabazitaxel]. The optimal sequence is currently not defined. An increasing number of pts are...
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要